Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Biological Chemistry|May 14, 2013
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genesBettina Grismayer, Sumito Sato, Charlotte Kopitz, et al.
Molecular Medicine (Cambridge, Mass.)|February 8, 2020
Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patientsWeiwei Gong, Yueyang Liu, Sarah Preis, et al.
Biological Chemistry|June 28, 2006
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cellsPanagiotis Prezas, Matthias J E Arlt, Petar Viktorov, et al.
Biological Chemistry|December 10, 2016
Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancerShuo Zhao, Julia Dorn, Rudolf Napieralski, et al.
Biological Chemistry|September 4, 2013
Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancerJulia Dorn, Apostolos Gkazepis, Matthias Kotzsch, et al.
Cancers|January 11, 2022
tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and ProgressionKonstantina Panoutsopoulou, Tobias Dreyer, Julia Dorn, et al.
British Journal of Cancer|March 22, 2022
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancerStefanie Seitz, Tobias F Dreyer, Christoph Stange, et al.
International Journal of Molecular Medicine|January 22, 2008
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISAJulia C Biermann, Leon Holzscheiter, Matthias Kotzsch, et al.
Biological Chemistry|April 5, 2002
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeuticsElke Guthaus, Markus Bürgle, Niko Schmiedeberg, et al.
International Journal of Oncology|January 13, 2018
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patientsMagdalena Absmaier, Rudolf Napieralski, Tibor Schuster, et al.
Pageof 13